Healthy Life

The global biotech and medical market reached an all-time high in 2021 (with over USD 79 billion in venture capital investment, according to Silicon Valley Bank), a record number of unicorns startups were founded, and investment in digital medicine more than doubled. The global venture capital market has already seen a major decrease in funding of 19% as of the second quarter of 2022 (according to CBInsights). Entrepreneurs and industries are currently facing a number of challenges: the disruption of technological chains, difficulties in production, changes in commercialization strategies, new models of cooperation and financing, and difficulties in entering the international arena. During the session, experts will discuss how venture capital has been transformed and where it’s going, what technologies are currently in demand among investors and the industry, how to support talented developers of medical technologies, what the target markets for international commercialization are, and whether domestic entrepreneurs can replace technologies that have left the country.

Moderator
Kirill Kaem, Senior Vice-President for Innovations, Skolkovo Foundation

Kirill Kaem

Senior Vice-President for Innovations, Skolkovo Foundation

Kirill Kaem, whose family have been doctors for no fewer than seven generations, graduated from the Kirov State Medical Academy in Nizhny Novgorod in 1992. Five years later he graduated with distinction from the economics department at the Lobachevsky State University, after successfully completing his studies in Russia and the USA on an MBA program run jointly with Taylor University. He has over 20 years' experience in senior management roles, including 15 years as a CEO at the corporation's various international branches. He specializes in launching start-ups in new regions and countries, and new business areas at major firms. From 1992 to 1994 he owned his own business, distributing medical equipment and pharmaceuticals. In 1995 Kirill Kaem set up a network of regional outlets for the Swedish company Oriflame in the Volga Region, which helped it become one of the region's biggest tax-payers. In the year 2000 he began working in Germany, in the central office of the company Varta. After Varta's merger with the American group Spectrum Brands, he spent eight years in overall charge of the company's operations in Russia. In 2008 he relaunched the German and American holding JAFRA International in Russia, improving profit margins by 40%. In 2009 he took control of the Russian holding Hygiene Kinetics, the biggest manufacturer in the market for domestic paper and cellulose products. Within two years the company's sales growth was several times higher than average growth in the sector, thanks to the introduction of new technologies. From 2011 to 2013 he headed up a new area of business at 'Alpha Group' - the biggest federal chain of clinics, 'Alpha Health Centre', where in the space of a year he managed to double revenue, whilst the chain itself saw profits rise by over a third. From 2013 onwards he has been a member of the Board of Directors and a co-founder of the international medical centre 'Medcluster', set up at the initiative of Sberbank in partnership with Strategy Group Partners, with Johns Hopkins Medicine International as a potential partner. From 2013-2017 he was director of the Skolkovo Foundation’s biomed cluster.

Panellists
Dmitry Peskov, Head of Young Professionals Direction, Agency of Strategic Initiatives; General Director, Platform of the National Technology Initiative; Special Representative of the President of the Russian Federation on Digital and Technological Development
Vikram Singh Punia, President, Pharmasyntez Group of Companies
Oleg Teplov, Chief Executive Officer, VEB Ventures
Faina Filina, Director for External Communications, International Medical Cluster Foundation
Mikhail Tsyferov, Managing Director, Winter Capital Investment Foundation, President, Petrovax Pharm

Dmitry Peskov

Head of Young Professionals Direction, Agency of Strategic Initiatives; General Director, Platform of the National Technology Initiative; Special Representative of the President of the Russian Federation on Digital and Technological Development

Vikram Singh Punia

President, Pharmasyntez Group of Companies

Born on March 15, 1973 in Jaipur, India. Russian citizen.
Graduated from Birla Public School in Pilani. In 1992 started his higher education in Russia, at Irkutsk State Medical University. Later graduated from the Far Eastern Federal University, majoring in Finance and Credit. Married, with three children.
Founder of Pharmasyntez, member of the Leaders’ Club to Promote Business Initiatives (a non-profit partnership), Co-Chairman of the Business Council for Cooperation with India, participant in several investment forums and business missions.
Pharmasyntez manufactures medicinal drugs for socially significant diseases, such as tuberculosis, HIV/AIDS, cancer, hepatitis and diabetes. The company’s profile includes over 113 various pharmaceutical forms and dosages – caps, pills, granules, IV solutions, sterile dry powders, solutions for injection and lyophilisates. Currently Pharmasyntez has five GMP compliant manufacturing facilities in the following Russian cities: Saint Petersburg, Tyumen, Bratsk, Irkutsk and Ussuriysk. The company employs over 1500 qualified specialists.
Pharmasyntez was number one Russian pharmaceutical manufacturer based on hospital purchases in 2016 (and No. 5 out of all pharmaceutical manufacturers, based on hospital purchases records). In 2016 it also became the fastest growing Russian manufacturing company with the revenue of 12 billion, which has doubled in comparison with 2014.
Currently Pharmasyntez is Russia’s leader in manufacturing medicinal agents for tuberculosis, retrovirus and cancer. Farmasintez does innovative R&D and exports pharmaceutical agents from Russia. The company is Irkutsk’s biggest tax payer.

Oleg Teplov

Chief Executive Officer, VEB Ventures

Oleg Teplov is the Chief Executive Officer of VEB Innovations, a subsidiary of Vnesheconombank (VEB) Group, a Russian economist, banker, and financier. He is one of the creators of the National Technology Initiative state program.

Oleg Teplov has been working in the finance industry and public sector for about 20 years, specializing in technological development of the Russian economy. Before joining VEB Innovations, Oleg held the position of referent at the Expert Directorate with the President of the Russian Federation, where he was involved in the development and implementation of the National Technology Initiative (NTI) and drafting the Digital Economy of Russia state program. As a referent at the directorate, he created the system of NTI governance and expansion and developed the National Ranking of Investment Climate in the Constituent Territories of the Russian Federation.

Oleg also leads the Strategic Planning Unit of the Economy and Finance Department at the Executive Office of the Government of Russia, as well as the Strategic Planning Department at the Ministry of Economic Development, where he coordinated the activities of the Strategic Initiatives Agency, Industrial Development Fund, Roseximbank, MSP Bank, and Russian Direct Investment Fund. He also held executive positions in major Russian banks and the global “Big Four” auditing firms.

At present, VEB Innovations under Oleg Teplov's management makes high-risk direct investments in technology-related projects, creates venture funds jointly with major Russian corporations and global partners, as well as fostering investment and technology cooperation with R&D centers, major businesses, and development institutions.

Special attention in his activities is paid to high-potential ICT (information and communication technology) and other projects for the space industry, vertical marketplace initiatives, as well as investments in artificial intelligence, robotics, online education services, and telemedicine. Pharmaceuticals, biotechnology, and new energy-related technologies are prioritized as well.

Mikhail Tsyferov

President, Member of the Board of Directors, Petrovax Pharm

Before joining Petrovax in 2018, Mikhail Tsyferov gained extensive experience in a number of large investment companies.
From 2018 to present – President of NPO Petrovax Pharm LLC (part of the Interros Group), Member of the Board of Directors.
From 2016 to present – Managing Director of the Winter Capital Fund.
From 2008 to 2016 – manager of the investment department of Interros.
From 2007 to 2008 – employee of the capital markets department at Renaissance Capital.
Acted as an investor in more than 20 Private equity / VC transactions.
He graduated from the School of International Economic Relations of MGIMO (Moscow State Institute of International Relations) in 2007.

Front row participants
Eric Brovko, Founder and CEO, Zdorovye Goroda
Albert Gayfullin, CEO, PharmMedPolis RT
Igor Shaderkin, Head of the Healthcare Laboratory, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov "of the Ministry of Health of the Russian Federation

Eric Brovko

Founder, My Health platform; Deputy Chairman, Commission on Informatization, Science and Innovations in Healthcare, Public Council of the Ministry of Health of the Russian Federation

Igor Shaderkin

Head of the Healthcare Laboratory, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov "of the Ministry of Health of the Russian Federation